Page 2 - Compass Pathways News Today

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 3,340,000 shares, an increase of 6.7% from the March 31st total of 3,130,000 shares. Based on an average trading volume of 705,600 shares, the days-to-cover ratio […]

BioPharma

LONDON, May 02, 2024 -- Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions , one of...

COMPASS Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, Benzinga reports. Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of COMPASS […]

COMPASS Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. A number of other equities research analysts also recently commented on CMPS. HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares […]

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the transaction, the insider now directly owns 3,986,523 shares […]

Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain ... LSD," and he made sure his interview did not disappoint. Mind Medicine Inc. (NASDAQ:MNMD) sees a massive market opportunity ahead, citing 21% of U.S. adults with an anxiety disorder, an estimated 4.4% of U.S. adults with attention-deficit/hyperactivity disorder (ADHD) and a $461 billion economic cost from autism s...

Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) have been given an average rating of “Buy” by the six research firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have updated their coverage […]

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in […]

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) major shareholder Ekaterina Malievskaia sold 25,750 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the completion of the sale, the insider now directly owns 4,036,154 shares […]